Healthcare provider profile · identity verified

Johnny C. Lin, MD

Family Practice · LOS ANGELES, CA · NPI 1770642357

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	379	225
Amlodipine Besylate	Amlodipine Besylate	174	110
Lisinopril	Lisinopril	172	94
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	167	96
Losartan Potassium	Losartan Potassium	135	83
Levothyroxine Sodium	Levothyroxine Sodium	128	77
Rosuvastatin Calcium	Rosuvastatin Calcium	126	93
Omeprazole	Omeprazole	104	54
Metformin Hcl	Metformin Hcl	99	54
Tamsulosin Hcl	Tamsulosin Hcl	92	50
Albuterol Sulfate Hfa	Albuterol Sulfate	86	55
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	86	51
Hydrochlorothiazide	Hydrochlorothiazide	84	48
Meloxicam	Meloxicam	77	53
Alendronate Sodium	Alendronate Sodium	71	39
Glipizide	Glipizide	68	36
Trazodone Hcl	Trazodone Hcl	63	34
Pradaxa	Dabigatran Etexilate Mesylate	61	34
Atenolol	Atenolol	60	48
Gabapentin	Gabapentin	55	34
Pantoprazole Sodium	Pantoprazole Sodium	55	35
Metformin Hcl Er	Metformin Hcl	53	38
Simvastatin	Simvastatin	53	39
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	52	25
Ibuprofen	Ibuprofen	50	27
Potassium Chloride	Potassium Chloride	48	34
Metoprolol Tartrate	Metoprolol Tartrate	47	31
Morphine Sulfate Er	Morphine Sulfate	43	11
Alprazolam	Alprazolam	38	32
Furosemide	Furosemide	37	24
Naproxen	Naproxen	36	13
Bisoprolol Fumarate	Bisoprolol Fumarate	35	17
Finasteride	Finasteride	35	19
Fluoxetine Hcl	Fluoxetine Hcl	35	22
Humulin N	Insulin Nph Human Isophane	34	16
Triamcinolone Acetonide	Triamcinolone Acetonide	34	25
Tramadol Hcl	Tramadol Hcl	30	25
Donepezil Hcl	Donepezil Hcl	26	12
Terazosin Hcl	Terazosin Hcl	25	16
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	24	24
Allopurinol	Allopurinol	24	16
Lovastatin	Lovastatin	24	12
Ozempic	Semaglutide	24	13
Warfarin Sodium	Warfarin Sodium	23	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	23	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	15
Famotidine	Famotidine	22	11
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	22	suppressed
Jardiance	Empagliflozin	22	12
Sertraline Hcl	Sertraline Hcl	22	19
Pravastatin Sodium	Pravastatin Sodium	19	11
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	18	12
Lorazepam	Lorazepam	16	15
Memantine Hcl	Memantine Hcl	16	suppressed
Ondansetron Odt	Ondansetron	16	13
Prednisone	Prednisone	16	16
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Cephalexin	Cephalexin	15	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	15
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Lactulose	Lactulose	14	12
Montelukast Sodium	Montelukast Sodium	14	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	13
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Topiramate	Topiramate	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	13	13
Duloxetine Hcl	Duloxetine Hcl	13	11
Humulin R	Insulin Regular, Human	13	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	13	suppressed
Oxycodone Hcl	Oxycodone Hcl	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Temazepam	Temazepam	12	suppressed
Carvedilol	Carvedilol	11	suppressed
Diazepam	Diazepam	11	suppressed
Eliquis	Apixaban	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error